SHANGHAI, March 6 - Chinese regulators have granted approval for Pfizer’s GLP-1 treatment Xianweiying to be used for long-term weight management in adults who are overweight or obese, the US drugmaker said on its WeChat account on Friday. The approval introduces Pfizer’s ecnoglutide into a market that analysts expect to be worth billions in coming years.
Xianweiying belongs to the class of GLP-1 receptor agonists, a group of injectable therapies already marketed in China by companies such as Novo Nordisk, Eli Lilly, and Innovent Biologics. Market activity for these drugs has been notable on major Chinese e-commerce platforms. Investment bank Jefferies reported that sales of Novo Nordisk’s Wegovy on Alibaba’s Tmall and JD.com reached 260 million yuan in 2025, while Innovent’s Xinermei logged 416 million yuan during the same period, the bank said. Jefferies translated those figures to roughly $38 million and $61 million respectively.
Sciwind Biosciences, the Hangzhou-based firm that licensed mainland China commercialisation rights to Pfizer in February, called the approval "a breakthrough in field of weight management" on its website. Sciwind had earlier described the licensing arrangement with Pfizer as "an important first step to advance Pfizer’s global strategy in the metabolic field in China."
Ecnoglutide is already approved in China as a treatment for Type II diabetes. Pfizer did not immediately respond to requests for comment on pricing or a launch timetable for the new weight-management indication in China.
The news also intersects with investor-facing analytics. A promotional note accompanying the announcement highlighted that ProPicks AI evaluates Pfizer (PFE) alongside thousands of other companies every month using more than 100 financial metrics. That system, the note said, applies AI to generate stock ideas by assessing fundamentals, momentum, and valuation, and cited past notable winners such as Super Micro Computer, which it listed at +185%, and AppLovin at +157%.
As the GLP-1 class gains traction in China, the addition of Pfizer’s Xianweiying to the roster underscores increased competition among multinational and domestic drugmakers. Market participants and stakeholders in pharmaceuticals and health-care services will likely monitor pricing decisions and the timing of a commercial launch closely.
Summary
China has approved Pfizer’s ecnoglutide (Xianweiying) for long-term weight management in overweight and obese adults. The injection joins other GLP-1 receptor agonists sold locally, and comes after Pfizer licensed mainland China commercialisation rights from Sciwind Biosciences in February. Sales data reported by Jefferies show significant e-commerce activity for competing products in 2025. Pfizer has not provided immediate comment on pricing or a launch date for the new indication.